Serum level of HER-2/neu in patients with gastric cancer: Correlation with HER-2/neu overexpression in gastric carcinoma tissue

Tumor Biology

Volumn 21, Issue 3, 2000, Pages 139-144

  Kono, Koji ^a   Naganuma, Hiroshi ^a   Sekikawa, Takayoshi ^a   Amemiya, Hideki ^a   Takahashi, Akihiro ^a   Iizuka, Hidehiko ^a   Matsumoto, Yoshiro ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Gastric cancer; HER 2 neu; HER 2 neu, serum; Overexpression

Indexed keywords

ARTICLE; CARDIA CARCINOMA; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0034055336     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030120     Document Type: Article

References (26)

1. Coussens L, Yang-Feng L, Liao YC, Chen E, Gray A, Mcgrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1136.
2. Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-184.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DF, Levin WJ, Stuart S, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-712.
4. Yonemura Y, Ninomiya I, Ohoyama S, Kimura H, Yamaguchi A, Fushida S, Kosaka T, Miwa K, Miyazaki I, Endou Y, Tanaka M, Sasaki T: Expression of c-erbB-2 oncoprotein in gastric carcinoma. Cancer 1991;67:2914-2918.
5. Uchino S, Tsuda H, Maruyama K, Kinoshita T, Sasako M, Saito T, Kobayashi M, Hirohashi S: Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993;72:3179-3184.
6. Tateishi M, Toda T, Minamisono Y, Nagasaki S: Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 1992;49:209-212.
7. Ohguri T, Sato Y, Koizumi W, Saigenji K, Kameya T: An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymphnode metastases: Is the c-erbB-2 protein really a prognostic indicator? Int J Cancer 1993;53:75-79.
8. Ishikawa T, Kobayshi M, Mai M, Suzuki T, Ooi A: Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Am J Pathol 1997;151:761-768.
9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2 neu oncogene. Science 1987;235:177-182.
10. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-1128.
11. Zhou DJ, Ahuja H, Cline MJ: Protooncogene abnormalities in human breast cancer: c-erbB2 amplification does not correlate with recurrence of disease. Oncogene 1989;4:105-108.
12. Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991;51:944-948.
13. Fisk B, Blevins TL, Wharton JT, Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte line. J Exp Med 1995;181:2109-2117.
14. Linehan DC, Goedegebuure PS, People GE, Rogers SO, Eberlein TJ: Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 1995;155:4486-4491.
15. Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W: HER-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998;58:732-736.
16. Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y, Kiessling R: Identification of HER-2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 1998;78:202-208.
17. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhangan R, Styles J, Rudenstam CM, Golouh R, Reed R: Prognostic importance of c-erbB-2 expression in breast cancer. International Breast Cancer Study Group. J Clin Oncol 1992;10:1049-1056.
18. Zabrecky JR, Lam T, McKenzie SJ, Carney W: The extracellular domain of p 185 neu is released from the surface of human breast carcinoma cell, SK-BR-3. J Biol Chem 1991;266:1716-1720.
19. Langton BC, Crenshaw MC, Chao LA, Stuart SG, Akita RW, Jackson JE: An antigen immunologically related to the external domain of gp 185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. Cancer Res 1991;51:2593-2598.
20. neu in human ovarian cancer. Cancer 1993;71:3942-3946.
21. Molina R, Jo J, Zanon G, Filella X, Farrus B, Munoz M, Latre ML, Pahisa J, Velasco M, Fernandez P, Estape J, Ballesta AM: Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: Comparison with caricnoembryonic antigen and CA15.3. Br J Cancer 1996;74:1126-1131.
22. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, Farrus B, Latre ML, Escriche C, Estape J, Ballesta AM: c-erbB-2 oncoprotein, CEA, and CA15-3 in patients with breast cancer: Prognostic value. Breast Cancer Res Treat 1998;51:109-119.
23. Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma, first English edition. Tokyo, Kenehara, 1993.
24. Gusterson BA, Gullick WJ, Venter DJ, Powles TJ, Elliott C, Ashley S, Tidy A, Harrison S: Immunohistochemical localization of c-erbB-2 in human breast carcinomas. Mol Cell Probes 1987;1:383-391.
25. Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M, Ballesta AM: Serum levels of c-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumor Biol 1997;18:188-196.
26. Leitzel K, Teramoto Y, Konrad K, Chinchilli V, Volas G, Grossberg H: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-1135.